Colorectal carcinogenesis: Review of human and experimental animal studies

Journal of Carcinogenesis

Volumn 8, Issue , 2009, Pages

  Tanaka, Takuji ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Human and animal investigation; Pre neoplasia

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOGEN; DOCUSATE SODIUM;

ADENOMATOUS POLYP; CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CELL PROLIFERATION; CELL RENEWAL; COLITIS; COLON CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; DEVELOPED COUNTRY; DISEASE MODEL; ENTERITIS; EPITHELIUM CELL; EPITHELIUM DYSPLASIA; HUMAN; INTESTINE FUNCTION; MORPHOLOGY; NONHUMAN; PATHOLOGICAL ANATOMY; PRECANCER; REVIEW;

EID: 65449180675     PISSN: None     EISSN: 14773163     Source Type: Journal    
DOI: 10.4103/1477-3163.49014     Document Type: Review

References (191)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008;44:1345-89.
3. Weisburger JH. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 1991;53:226S-37S.
4. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59:27-41.
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
6. Kuriki K, Tajima K. The increasing incidence of colorectal cancer and the preventive strategy in Japan. Asian Pac J Cancer Prev 2006;7:495-501.
7. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-50.
8. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80.
9. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111:241-50.
10. Potten CS. Stem cells in gastrointestinal epithelium: Numbers, characteristics and death. Philos Trans R Soc Lond B Biol Sci 1998;353:821-30.
11. Deschner EE, Lipkin M. Proliferative patterns in colonic mucosa in familial polyposis. Cancer 1975;35:413-8.
12. Ponz de Leon M, Roncucci L, Di Donato P, Tassi L, Smerieri O, Amorico MG, et al. Pattern of epithelial cell proliferation in colorectal mucosa of normal subjects and of patients with adenomatous polyps or cancer of the large bowel. Cancer Res 1988;48:4121-6.
13. Deschner EE, Winawer SJ, Katz S, Katzka I, Kahn E. Proliferative defects in ulcerative colitis patients. Cancer Invest 1983;1:41-7.
14. Roncucci L, Ponz de Leon M, Scalmati A, Malagoli G, Pratissoli S, Perini M, et al. The influence of age on colonic epithelial cell proliferation. Cancer 1988;62:2373-7.
15. Scalmati A, Roncucci L, Ghidini G, Biasco G, Ponz de Leon M. Epithelial cell kinetics in the remaining colorectal mucosa after surgery for cancer of the large bowel. Cancer Res 1990;50:7937-41.
16. Bach SP, Renehan AG, Potten CS. Stem cells: The intestinal stem cell as a paradigm. Carcinogenesis 2000;21:469-76.
17. Bykorez AI, Yu DI. Gastrointestinal stem cells and their role in carcinogenesis. Int Rev Cytol 1984;90:309-73.
18. Pretlow TP, Barrow BJ, Ashton WS, O'Riordan MA, Pretlow TG, Jurcisek JA, et al. Aberrant crypts: Putative preneoplastic foci in human colonic mucosa. Cancer Res 1991;51:1564-7.
19. Pretlow TP, O'Riordan MA, Somich GA, Amini SB, Pretlow TG. Aberrant crypts correlate with tumor incidence in F344 rats treated with azoxymethane and phytate. Carcinogenesis 1992;13:1509-12.
20. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995;93:55-71.
21. Potten CS, Kellett M, Rew DA, Roberts SA. Proliferation in human gastrointestinal epithelium using bromodeoxyuridine in vivo: Data for different sites, proximity to a tumour, and polyposis coli. Gut 1992;33:524-9.
22. Boman BM, Fields JZ, Bonham-Carter O, Runquist OA. Computer modeling implicates stem cell overproduction in colon cancer initiation. Cancer Res 2001;61:8408-11.
23. Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ, Boman BM. Evidence that APC regulates survivin expression: A possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001;61:8664-7.
24. Greaves LC, Preston SL, Tadrous PJ, Taylor RW, Barron MJ, Oukrif D et al. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. Proc Natl Acad Sci U S A 2006;103:714-9.
25. Preston SL, Wong WM, Chan AO, Poulsom R, Jeffery R, Goodlad RA, et al. Bottom-up histogenesis of colorectal adenomas: Origin in the monocryptal adenoma and initial expansion by crypt fission. Cancer Res 2003;63:3819-25.
26. Bjerknes M, Cheng H, Hay K, Gallinger S. APC mutation and the crypt cycle in murine and human intestine. Am J Pathol 1997;150:833-9.
27. Shih IM, Wang TL, Traverso G, Romans K, Hamilton SR, Ben-Sasson S, et al. Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci USA 2001;98:2640-5.
28. Wasan HS, Park HS, Liu KC, Mandir NK, Winnett A, Sasieni P, et al. APC in the regulation of intestinal crypt fission. J Pathol 1998;185:246-55.
29. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL. Clinical implications and utility of field cancerization. Cancer Cell Int 2007;7:2.
30. Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snel MH, et al. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 2001;7:1523-32.
31. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Van Der Wal JE, Snow GB, Leemans CR, et al. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol 2002;161:1051-60.
32. Aivado M, Gynes M, Gorelov V, Schmidt WU, Röher HD, Goretzki PE. "Field cancerization": An additional phenomenon in development of colon tumors? K-ras codon 12 mutations in normal colonic mucosa of patients with colorectal neoplasms. Chirurg 2000;71:1230-4.
33. Leedham SJ, Graham TA, Oukrif D, McDonald SA, Rodriguez-Justo M, Harrison RF, et al. Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 2009;136:542-50 e6.
34. Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA. Aberrant crypts in human colonic mucosa: Putative preneoplastic lesions. J Cell Biochem 1992;16G:55-62.
35. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-84.
36. Yamada Y, Yoshimi N, Hirose Y, Kawabata K, Matsunaga K, Shimizu M, et al. Frequent b-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000;60:3323-7.
37. Caderni G, Femia AP, Giannini A, Favuzza A, Luceri C, Salvadori M, et al. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res 2003;63:2388-92.
38. Femia AP, Giannini A, Fazi M, Tarquini E, Salvadori M, Roncucci L, et al. Identification of mucin depleted foci in the human colon. Cancer Prev Res (Phila Pa) 2008;1:562-7.
39. Mori H, Hata K, Yamada Y, Kuno T, Hara A. Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem Biol Interact 2005;155:1-9.
40. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings. Cancer Lett 1987;37:147-51.
41. Bird RP, Good CK. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 2000;112-113:395-402.
42. Raju J. Azoxymethane-induced rat aberrant crypt foci: Relevance in studying chemoprevention of colon cancer. World J Gastroenterol 2008;14:6632-5.
43. Tanaka T, Miyamoto, S, Suzuki R, Yasui, Y. Chemoprevention of colon carcinogenesis by dietary non-nutritive compounds. Curr Nuetraceut Res 2006;4:127-52.
44. Bird RP, Good CK. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 2000;112/ 113:395-402.
45. Yamada Y, Yoshimi N, Hirose Y, Matsunaga K, Katayama M, Sakata K, et al. Sequential analysis of morphological and biological properties of beta-catenin-accumulated crypts, probable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 2001;61:1874-8.
46. Konishi F, Morson BC. Pathology of colorectal adenomas: A colonoscopic survey. J Clin Pathol 1982;35:830-41.
47. Hardy RG, Meltzer SJ, Jankowski JA. ABC of colorectal cancer: Molecular basis for risk factors. BMJ 2000;321:886-9.
48. Muto T, Kamiya J, Sawada T, Konishi F, Sugihara K, Kubota Y, et al. Small "flat adenoma" of the large bowel with special reference to its clinicopathologic features. Dis Colon Rectum 1985; 28:847-51.
49. Yao T, Tada S, Tsuneyoshi M. Colorectal counterpart of gastric depressed adenoma: A comparison with flat and polypoid adenomas with special reference to the development of pericryptal fibroblasts. Am J Surg Pathol 1994;18:559-68.
50. Adachi M, Okinaga K, Muto T. Flat adenoma of the large bowel: Re-evaluation with special reference to central depression. Dis Colon Rectum 2000;43:782-7.
51. Muto T, Nagawa H, Watanabe T, Masaki T, Sawada T. Colorectal carcinogenesis: historical review. Dis Colon Rectum 1997;40:S80-5.
52. Teoh HH, Delahunt B, Isbister WH. Dysplastic and malignant areas in hyperplastic polyps of the large intestine. Pathology 1989;21:138-42.
53. Jass JR, Iino H, Ruszkiewicz A, Painter D, Solomon MJ, Koorey DJ, et al. Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum. Gut 2000;47:43-9.
54. Longacre TA, Fenoglio-Preiser CM. Mixed hyperplastic adenomatous polyps/ serrated adenomas: A distinct form of colorectal neoplasia. Am J Surg Pathol 1990;14:524-37.
55. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer: A population-based study. N Engl J Med 1990;323:1228-33.
56. Odze R. Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol 2003;16:347-58.
57. Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008;14:378-89.
58. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, et al. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46.
59. Miyamoto S, Yasui Y, Murakami A, Tanaka T. Molecular mechanism of colorectal carcinogenesis. In Cancer: Disease Progression and Chemoprevention. In: Tanaka T, editor. Kerala, India: Research Signpost; 2007. p. 45-56.
60. Ebert MP, Schmid R, Röcken C. Need for a paradigm shift in cancer prevention and clinical oncology. Expt Rev Anticancer Ther 2007;7:1363-7.
61. Freedman L. Quantitative science methods for biomarker validation in chemoprevention trials. Cancer Biomark 2007;3:135-40.
62. Gao JX. Cancer stem cells: the lessons from pre-cancerous stem cells. J Cell Mol Med 2008;12:67-96.
63. Kim YS, Maruvada P, Milner JA. Metabolomics in biomarker discovery: Future uses for cancer prevention. Future Oncol 2008;4:93-102.
64. Kingsley BS, Schmeichel KL, Rubin CH. An update on cancer cluster activities at the Centers for Disease Control and Prevention. Environ Health Perspect 2007;115:165-71.
65. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
66. Ichii S, Horii A, Nakatsuru S, Furuyama J, Utsunomiya J, Nakamura Y: Inactivation of both APC alleles in an early stage of colon adenomas in a patient with familial adenomatous polyposis (FAP). Hum Mol Genet 1992;1:387-90.
67. Sieber OM, Tomlinson IP, Lamlum H: The adenomatous polyposis coli (APC) tumour suppressor - genetics, function and disease. Mol Med Today 2000;6:462-9.
68. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-7.
69. Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 1994;54:5527-30.
70. Takahashi M, Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 2004;95:475-80.
71. Ilyas M. Wnt signalling and the mechanistic basis of tumour development. J Pathol 2005;205:130-44.
72. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001;1:55-67.
73. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
74. Hulit J, Wang C, Li Z, Albanese C, Rao M, Di Vizio D, et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 2004;24:7598-611.
75. Leevers SJ, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994;369:411-4.
76. Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF. Activation of Raf as a result of recruitment to the plasma membrane. Science 1994;264:1463-7.
77. Moodie SA, Willumsen BM, Weber MJ, Wolfman A. Complexes of Ras: GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993;260:1658-61.
78. Warne PH, Viciana PR, Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 1993;364:352-5.
79. Koide H, Satoh T, Nakafuku M, Kaziro Y. GTP-dependent association of Raf-1 with Ha-Ras: Identification of Raf as a target downstream of Ras in mammalian cells. Proc Natl Acad Sci U S A 1993;90:8683-6.
80. Valencia A, Chardin P, Wittinghofer A, Sander C. The ras protein family: Evolutionary tree and role of conserved amino acids. Biochemistry 1991;30:4637-48.
81. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990;247:49-56.
82. Thiagalingam S, Lengauer C, Leach FS, Schutte M, Hahn SA, Overhauser J, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-6.
83. Itoh F, Hinoda Y, Ohe M, Ohe Y, Ban T, Endo T, et al. Decreased expression of DCC mRNA in human colorectal cancers. Int J Cancer 1993;53:260-3.
84. Goi T, Yamaguchi A, Nakagawara G, Urano T, Shiku H, Furukawa K. Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. Br J Cancer 1998;77:466-71.
85. Schmitt CA, Thaler KR, Wittig BM, Kaulen H, Meyer zum Buschenfelde KH, Dippold WG. Detection of the DCC gene product in normal and malignant colorectal tissues and its relation to a codon 201 mutation. Br J Cancer 1998;77:588-94.
86. Tarafa G, Villanueva A, Farre L, Rodriguez J, Musulen E, Reyes G, et al. DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination. Oncogene 2000;19:546-55.
87. Gotley DC, Reeder JA, Fawcett J, Walsh MD, Bates P, Simmons DL, et al. The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases. Oncogene 1996;13:787-95.
88. Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, et al. Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell 1996;87:175-85.
89. Serafini T, Kennedy TE, Galko MJ, Mirzayan C, Jessell TM, Tessier-Lavigne M. The netrins define a family of axon outgrowth-promoting proteins homologous to C. elegans UNC-6. Cell 1994;78:409-24.
90. Serafini T, Colamarino SA, Leonardo ED, Wang H, Beddington R, Skarnes WC, et al. Netrin-1 is required for commissural axon guidance in the developing vertebrate nervous system. Cell 1996;87:1001-14.
91. Forcet C, Stein E, Pays L, Corset V, Llambi F, Tessier-Lavigne M, et al. Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MAPK activation. Nature 2002;417:443-7.
92. Velcich A, Corner G, Palumbo L, Augenlicht L. Altered phenotype of HT29 colonic adenocarcinoma cells following expression of the DCC gene. Oncogene 1999;18:2599-606.
93. Chen YQ, Hsieh JT, Yao F, Fang B, Pong RC, Cipriano SC, et al. Induction of apoptosis and G2/M cell cycle arrest by DCC. Oncogene 1999;18:2747-54.
94. Liu J, Yao F, Wu R, Morgan M, Thorburn A, Finley RL, et al. Mediation of the DCC apoptotic signal by DIP13 alpha. J Biol Chem 2002;277:26281-5.
95. Forcet C, Ye X, Granger L, Corset V, Shin H, Bredesen DE, et al. The dependence receptor DCC (deleted in colorectal cancer) defines an alternative mechanism for caspase activation. Proc Natl Acad Sci U S A 2001;98:3416-21.
96. Mehlen P, Rabizadeh S, Snipas SJ, Assa-Munt N, Salvesen GS, Bredesen DE. The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 1998;395:801-4.
97. Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002;3:101-28.
98. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
99. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
100. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
101. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
102. Zhan Q, Carrier F, Fornace AJ. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 1993;13:4242-50.
103. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
104. Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, Augeri-Henmueller L, Shehee R, et al. Genomic instability in Gadd45a-deficient mice. Nat Genet 1999;23:176-84.
105. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995;80:293-9.
106. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000;288:1053-8.
107. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7:673-82.
108. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-94.
109. Jurgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC. Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A 1998;95:4997-5002.
110. Warthin AS. Heredity with referance to carcinoma. Arch Intern Med 1913;12:546-55.
111. Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol 2002;3:83-8.
112. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
113. Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study: The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997;113:1146-58.
114. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
115. Souza RF, Appel R, Yin J, Wang S, Smolinski KN, Abraham JM, et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat Genet 1996;14:255-7.
116. Yoshitaka T, Matsubara N, Ikeda M, Tanino M, Hanafusa H, Tanaka N, et al. Mutations of E2F-4 trinucleotide repeats in colorectal cancer with microsatellite instability. Biochem Biophys Res Commun 1996;227:553-7.
117. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967-9.
118. Kuramoto S, Oohara T. Flat early cancers of the large intestine. Cancer 1989;64:950-5.
119. Shimoda T, Ikegami M, Fujisaki J, Matsui T, Aizawa S, Ishikawa E. Early colorectal carcinoma with special reference to its development de novo. Cancer 1989;64:1138-46.
120. Kuramoto S, Oohara T. Minute cancers arising de novo in the human large intestine. Cancer 1988;61:829-34.
121. Kashida H, Kudo SE. Early colorectal cancer: concept, diagnosis, and management. Int J Clin Oncol 2006;11:1-8.
122. Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, et al. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 2002;12:253-65.
123. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:204-11.
124. Greenstein AJ. Cancer in inflammatory bowel disease. Mt Sinai J Med 2000;67:227-40.
125. Craft CF, Mendelsohn G, Cooper HS, Yardley JH. Colonic "precancer" in Crohn's disease. Gastroenterology 1981; 80:578-84.
126. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003;94:965-73.
127. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: Its role in health and disease. J Mol Med 2004;82:434-48.
128. Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am, J Pathol 2000;157:737-45.
129. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease. Cancer Res 2000;60:3333-7.
130. Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 2004;19:308-15.
131. Kim M, Miyamoto S, Yasui Y, Oyama T, Murakami A, Tanaka T. Zerumbone, a tropical ginger sesquiterpene, inhibits colon and lung carcinogenesis in mice. Int J Cancer 2009;124:264-71.
132. Miyamoto S, Epifano F, Curini M, Genovese S, Kim M, Ishigamori-Suzuki R, et al. A novel prodrug of 4′-geranyloxy-ferulic acid suppresses colitis-related colon carcinogenesis in mice. Nutr Cancer 2008;60:675-84.
133. Tanaka T, Yasui Y, Ishigamori-Suzuki R, Oyama T. Citrus compounds inhibit inflammation- and obesity-related colon carcinogenesis in mice. Nutr Cancer 2008;60:70-80.
134. Tanaka T, Oyama T, Yasui Y. Dietary supplements and colorectal cancer. Curr Nuetraceut Res 2008;6:165-88.
135. Rosenberg DW, Giardina C, Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis 2009;30:183-96.
136. Reddy BS. Colon carcinogenesis models for chemoprevention studies. Hematol Oncol Clin North Am 1998;12:963-73.
137. Reddy BS, Rao CV. Colon cancer: A role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs. Drugs Aging 2000;16:329-34.
138. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, et al. Pathology of mouse models of intestinal cancer: Consensus report and recommendations. Gastroenterology 2003;124:762-77.
139. Taketo MM, Edelmann W. Mouse models of colon cancer. Gastroenterology 2009;136:780-98.
140. Fiala ES. Investigations into the metabolism and mode of action of the colon carcinogens 1,2-dimethylhydrazine and azoxymethane. Cancer 1977;40:2436-45.
141. Fiala ES, Stathopoulos C. Metabolism of methylazoxymethanol acetate in the F344 rat and strain-2 guinea pig and its inhibition by pyrazole and disulfiram. J Cancer Res Clin Oncol 1984;108:129-34.
142. Fiala ES, Bobotas G, Kulakis C, Wattenberg LW, Weisburger JH. Effects of disulfiram and related compounds on the metabolism in vivo of the colon carcinogen, 1,2-dimethylhydrazine. Biochem Pharmacol 1977;26:1763-8.
143. Wheeler LA, Soderberg FB, Goldman P. The reduction of N-hydroxy-4-acetylaminobiphenyl by the intestinal microflora of the rat. Cancer Res 1975;35:2962-8.
144. Grab DJ, Zedeck MS. Organ-specific effects of the carcinogen methylazoxymethanol related to metabolism by nicotinamide adenine dinucleotide-dependent dehydrogenases. Cancer Res 1977;37:4182-9.
145. Ward JM, Yamamoto RS, Brown CA. Pathology of intestinal neoplasms and other lesions in rats exposed to azoxymethane. J Natl Cancer Inst 1973;51:1029-39.
146. Maskens AP. Histogenesis and growth pattern of 1,2-dimethylhydrazine-induced rat colon adenocarcinoma. Cancer Res 1976;36:1585-92.
147. Filipe MI. Mucous secretion in rat colonic mucosa during carcinogenesis induced by dimethylhydrazine. A morphological and histochemical study. Br J Cancer 1975;32:60-77.
148. Ward JM. Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats. Lab Invest 1974;30:505-13.
149. Sunter JP, Appleton DR, Wright NA, Watson AJ. Pathological features of the colonic tumours induced in rats by the administration of 1,2-dimethylhydrazine. Virchows Arch B Cell Pathol 1978;29:211-23.
150. Chang WW. Histogenesis of colon cancer in experimental animals. Scand J Gastroenterol 1984;104:27-34.
151. Goldin BR. Chemical induction of colon tumors in animals: An overview. Prog Clin Biol Res 1988;279:319-33.
152. Haughn C, Uchal M, Raftopoulos Y, Rossi S, Santucci T, Torpey M, et al. Development of a total colonoscopy rat model with endoscopic submucosal injection of the cecal wall. Surg Endosc 2006;20:270-3.
153. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001;48:526-35.
154. van Hogezand RA, Eichhorn RF, Choudry A, Veenendaal RA, Lamers CB. Malignancies in inflammatory bowel disease: Fact or fiction? Scand J Gastroenterol Suppl 2002:48-53.
155. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. Novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
156. Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J, Ohkusa T. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 2002;17:1078-83.
157. Seril DN, Liao J, Yang GY, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: Studies in human and animal models. Carcinogenesis 2003;24:353-62.
158. Tanaka T, Kohno H, Murakami M, Shimada R, Kagami S. Colitis-related rat colon carcinogenesis induced by 1-hydroxyanthraquinone and methylazoxymethanol acetate (Review). Oncol Rep 2000;7:501-8.
159. Malaviya R, Ikeda T, Ross EA, Jakschik BA, Abraham SN. Bacteria - mast cell interactions in inflammatory disease. Am J Ther 1995;2:787-92.
160. Maeda H, Akaike T. Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Mosc) 1998;63:854-65.
161. Tanaka T, Yasui Y. Preclinical animal studies on chemoprevention of colorectal cancer. Clin Gastroenterol 2008;23:1669-76.
162. Kohno H, Suzuki R, Sugie S, Tanaka T. Beta-Catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1,2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci 2005;2005:69-76.
163. Tanaka T, Suzuki R, Kohno H, Sugie S, Takahashi M, Wakabayashi K. Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess beta-catenin gene mutations and increases immunoreactivity for beta-catenin, cyclooxygenase-2 and inducible nitric oxide synthase. Carcinogenesis 2005;26:229-38.
164. Suzuki R, Kohno H, Sugie S, Nakagama H, Tanaka T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis 2006;27:162-9.
165. Suzuki R, Kohno H, Sugie S, Tanaka T. Dose-dependent promoting effect of dextran sodium sulfate on mouse colon carcinogenesis initiated with azoxymethane. Histol Histopathol 2005;20:483-92.
166. Suzuki R, Kohno H, Sugie S, Tanaka T. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in mouse colon treated with azoxymethane and dextran sodium sulfate. Cancer Sci 2004;95:721-7.
167. Tanaka T, Kohno H, Suzuki R, Hata K, Sugie S, Niho N, et al. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: Inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer 2006;118:25-34.
168. Suzuki R, Miyamoto S, Yasui Y, Sugie S, Tanaka T. Global gene expression analysis of the mouse colonic mucosa treated with azoxymethane and dextran sodium sulfate. BMC Cancer 2007;7:84.
169. Tanaka T, Yasui Y, Tanaka M, Oyama T, Rahman KM. Melatonin suppresses AOM/DSS-induced large bowel oncogenesis in rats. Chem Biol Interact 2009;177:128-36.
170. Kohno H, Totsuka Y, Yasui Y, Suzuki R, Sugie S, Wakabayashi K, et al. Tumor-initiating potency of a novel heterocyclic amine, aminophenylnorharman in mouse colonic carcinogenesis model. Int J Cancer 2007;121:1659-64.
171. Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Kuno T, et al. Lack of enhancing effects of degraded lambda-carrageenan on the development of beta-catenin-accumulated crypts in male DBA/2J mice initiated with azoxymethane. Cancer Lett 2006;238:69-75.
172. Miyamoto S, Yasui Y, Tanaka T, Ohigashi H, Murakami A. Suppressive effects of nobiletin on hyperleptinemia and colitis-related colon carcinogenesis in male ICR mice. Carcinogenesis 2008;29:1057-63.
173. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985;45:1-8.
174. Tanaka T. Cancer chemoprevention. Cancer J 1992;5:11-6.
175. Tanaka T. Cancer chemoprevention by natural products (Review). Oncol Rep 1994;1:1139-55.
176. Tanaka T. Effect of diet on human carcinogenesis. Crit Rev Oncol/Hematol 1997;25:73-95.
177. Tanaka T. Chemoprevention of human cancer: Biology and therapy. Crit Rev Oncol/Hematol 1997;25:139-74.
178. Tanaka T, Mori H. Inhibition of colon carcinogenesis by non-nutritive constituents in foods. J Toxicol Pathol 1996;9:139-49.
179. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
180. Nagao M, Sugimura T. Multiple steps in carcinogenesis, multiple carcinogenic factors, and multiple primary tumors: can we develop an appropriate response for cancer prevention? Drug Metab Rev 1998;30:405-19.
181. Janakiram NB, Rao CV. Molecular biomarkers and targets for colorectal cancer prevention. Acta Pharmacol Sin 2008;29:1-20.
182. Yasui Y, Kim M, Oyama T, Tanaka T. Colorectal carcinogenesis and suppression of tumor development by inhibition of enzymes and molecular targets. Curr Enzyme Inhibitions 2009;5:1-26.
183. Reddy BS. The Fourth DeWitt S. Goodman lecture. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol Biomarkers Prev 2000;9:239-47.
184. Reddy BS. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 2004;44:26-35.
185. Reddy BS. Strategies for colon cancer prevention: Combination of chemopreventive agents. Subcell Biochem 2007;42:213-25.
186. Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004;555:107-19.
187. Rao CV. Regulation of COX and LOX by curcumin. Adv Exp Med Biol 2007;595:213-26.
188. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29-42.
189. Reddy BS, Rao CV. Chemoprophylaxis of colon cancer. Curr Gastroenterol Rep 2005;7:389-95.
190. Saleem M, Murtaza I, Tarapore R, Suh Y, Adhami VM, Johnson JJ, et al. Lupeol Inhibits proliferation of human prostate cancer cells by targeting {beta}-catenin signaling. Carcinogenesis 2009 in press.
191. Tsuchiya N, Ochiai M, Nakashima K, Ubagai T, Sugimura T, Nakagama H. SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis. Cancer Res 2007;67:9568-76.